Celexa (citalopram) and Lexapro (escitalopram) are more closely related than any other pair of brand-name antidepressants on the market. Escitalopram is literally one half of the citalopram molecule, isolated because researchers believed the other half was dead weight or even mildly counterproductive. That origin story shapes every practical difference between them, from dosing and side effects to how quickly they start working.
One Drug Inside Another
Citalopram, introduced in 1998, is what chemists call a racemic mixture. It contains two mirror-image versions of the same molecule: the S-enantiomer and the R-enantiomer. Think of them as left-hand and right-hand gloves made of the same material. When you swallow a citalopram tablet, you get both. Escitalopram, introduced four years later in 2002, is just the S-enantiomer on its own.1PubMed Central. Rise of escitalopram and the fall of citalopram
The reason this matters is that research found the S-enantiomer does all the therapeutic heavy lifting. It’s the piece that blocks the serotonin transporter and keeps serotonin active in the brain longer. The R-enantiomer does very little useful work at that transporter and, according to several lines of evidence, may actually interfere with the S-enantiomer’s binding.2PubMed. The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons In lab experiments, R-citalopram at clinically relevant concentrations slows down how quickly escitalopram latches onto the serotonin transporter, apparently by occupying a secondary binding site on the same protein.3PubMed. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant So escitalopram is not simply “half the dose of citalopram.” It’s the active ingredient freed from a molecular hitchhiker that may have been slowing it down.
Does the Purified Version Actually Work Better?
The short answer from pooled clinical data is yes, though the gap is not enormous. A meta-analysis combining data from multiple randomized trials found escitalopram significantly outperformed citalopram on standard depression rating scales, with roughly 1.7 more points of improvement on the MADRS at eight weeks. That may not sound dramatic, but the differences in real-world outcomes were clearer: escitalopram led to higher rates of both response and remission. The odds of responding to treatment were about 44% higher with escitalopram, and the odds of reaching remission were about 86% higher.4International Journal of Neuropsychopharmacology. Efficacy of escitalopram compared to citalopram: a meta-analysis
Pooled analyses from the broader clinical trial database paint a consistent picture: escitalopram tends to be more effective than citalopram in moderate-to-severe depression.5PubMed. Escitalopram: a review of its use in the management of major depressive disorder And the advantage isn’t limited to comparisons with citalopram alone. Review data suggest escitalopram performs at least as well as, and sometimes better than, other commonly prescribed SSRIs and SNRIs.6PubMed Central. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
A caveat worth keeping in mind: many of the head-to-head trials were funded by the manufacturer of escitalopram. That doesn’t make the findings wrong, but it does mean independent confirmation matters. The remission advantage is the most clinically meaningful part of the data, because getting all the way to remission, rather than just improving somewhat, is what actually changes someone’s day-to-day life.
A Faster Start
One of the more interesting differences shows up early in treatment. A pooled analysis of escitalopram trials in major depression found a statistically significant advantage for escitalopram over comparator antidepressants as early as day seven, with greater improvement on depression scales that persisted at every subsequent assessment. The advantage was most pronounced when escitalopram was compared against other SSRIs.7International Clinical Psychopharmacology. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Head-to-head, escitalopram shows both greater efficacy and faster onset of action than equivalent doses of citalopram in clinical trials, with quicker time to symptom relief.8PubMed. Escitalopram versus citalopram: the surprising role of the R-enantiomer For someone starting antidepressant treatment and dreading the standard two-to-four-week wait for noticeable effects, this difference can matter psychologically even if the absolute gap is modest. The proposed explanation ties back to the allosteric mechanism: without R-citalopram competing for access to the serotonin transporter, escitalopram may reach full therapeutic effect faster.
Treating Anxiety
Both citalopram and escitalopram are prescribed for anxiety, but escitalopram has built a stronger evidence base for generalized anxiety disorder specifically. In a controlled trial of over 300 patients with GAD, escitalopram at 10 to 20 mg per day produced significantly greater improvement than placebo on every prospectively defined measure.9PubMed. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study The benefit held across different subgroups, including patients with more severe depressive symptoms at the start, and extended to improvements in quality of life.10PubMed. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes
Pooled data from multiple GAD trials showed escitalopram beating placebo on anxiety scales from as early as the first or second week, and the advantage held through eight weeks of treatment. Even patients maintained at the lower 10 mg dose showed significantly greater improvement than those on placebo.11PubMed. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials Citalopram is used for anxiety too, but it lacks the same depth of dedicated GAD trial data, and escitalopram carries the specific FDA indication for GAD while citalopram does not.
Side Effects and the QT Question
The everyday side-effect profiles of citalopram and escitalopram look nearly identical. Patients taking either drug commonly report dry mouth, headache, nausea, diarrhea, insomnia, and ejaculatory problems.12PubMed Central. Rise of escitalopram and the fall of citalopram If you’ve been on one and your doctor switches you to the other, you’re unlikely to notice a dramatic change in how the drug makes you feel day to day.
The meaningful safety difference involves the heart. In 2011 and 2012, regulatory agencies flagged citalopram for dose-dependent prolongation of the QT interval, a measure of electrical activity in the heart that, when stretched too long, can in rare cases trigger dangerous arrhythmias. Citalopram’s maximum recommended dose was capped at 40 mg per day for adults and 20 mg per day for people over 65 as a result. A dedicated clinical study found that escitalopram was associated with substantially less QT prolongation than citalopram, and clinically relevant changes appeared only at supratherapeutic doses of 30 mg per day.13Medsafe. Citalopram and Escitalopram – Similar Risk of QT Prolongation? This cardiac safety gap is one of the main reasons prescribing has shifted toward escitalopram in recent years, particularly for older adults and anyone taking other medications that can affect heart rhythm.
Sexual Dysfunction
Sexual side effects are one of the top reasons people stop taking SSRIs, so how citalopram and escitalopram compare on this front matters. Unfortunately, neither drug looks great. A large pharmacovigilance analysis found that citalopram and escitalopram together were associated with a wide range of sexual dysfunction symptoms, from loss of libido to ejaculation problems to orgasm difficulties. They were the only antidepressants in the analysis linked to female orgasmic disorder specifically.14Sexual Medicine. Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis
A network meta-analysis comparing sexual dysfunction across second-generation antidepressants found that escitalopram carried a significantly higher risk of sexual problems than some other options, alongside paroxetine. Bupropion, by contrast, had significantly lower risk.15PubMed. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis The evidence doesn’t clearly separate citalopram from escitalopram on sexual side effects. In practical terms, if sexual dysfunction is your primary concern with an antidepressant, switching between these two is unlikely to solve it. A switch to a different class of antidepressant is a more productive conversation to have with your prescriber.
Dosing and How to Think About the Switch
Because escitalopram is the purified active half of citalopram, the dose conversion is straightforward: escitalopram’s equivalent dose is half that of citalopram.16Psychopharmacology Institute. Citalopram and Escitalopram: A Summary of Key Differences and Similarities If you’ve been taking 20 mg of citalopram, the roughly equivalent dose of escitalopram is 10 mg. In practice, most prescribers use common starting doses of 10 mg for escitalopram and 20 mg for citalopram, with maximum recommended doses of 20 mg and 40 mg respectively.
Switching between the two is generally considered simple because of the nearly identical pharmacology. Many doctors do a direct switch at equivalent doses without a taper-and-start period. That said, if you’re stable on one and it’s working, switching purely because escitalopram is the “newer, better” version isn’t always warranted. Plenty of people do well on citalopram, and the statistical advantages of escitalopram in clinical trials don’t mean every individual patient will feel better on it.
Younger and Older Patients
For children and adolescents, escitalopram has a slight regulatory edge. The FDA approved escitalopram for adolescent depression (ages 12 to 17) based on a positive randomized controlled trial. Citalopram also has a positive pediatric trial, but it does not carry a specific FDA approval for this age group. A review of the available evidence found one positive RCT each for escitalopram and citalopram in pediatric depression, with the overall data thin for both drugs.17PubMed Central. A review of escitalopram and citalopram in child and adolescent depression In practice, both are prescribed to younger patients, but escitalopram’s formal indication gives prescribers and families more confidence in its evidence base.
For older adults, the QT prolongation issue discussed earlier becomes especially relevant. Citalopram’s dose ceiling drops to 20 mg per day for people over 65, which can limit its effectiveness for patients who need higher doses. Escitalopram doesn’t carry the same degree of dose restriction in this population, giving prescribers more room to adjust. This is a practical advantage that has nudged many geriatric psychiatrists toward escitalopram as their default citalopram-class choice.
Pregnancy Considerations
Neither drug is considered risk-free during pregnancy, but the available data on escitalopram is somewhat reassuring regarding birth defects. A prospective study tracking over 200 pregnancies exposed to escitalopram found a major malformation rate of about 1.7%, which is within the expected background rate for the general population. However, spontaneous abortion rates were roughly double in both the escitalopram group and a comparison antidepressant group relative to unexposed controls, though this difference didn’t reach statistical significance. Escitalopram use was also associated with increased risk of low birth weight.18PubMed Central. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study The decision to use any antidepressant during pregnancy involves weighing these risks against the real dangers of untreated depression in the mother. That’s a conversation best had with a prescriber who knows your full medical picture, but neither citalopram nor escitalopram stands out as clearly safer than the other in pregnancy based on available evidence.
Cost and the Generic Landscape
Both citalopram and escitalopram have been available as generics for years, which has largely leveled the cost playing field. When escitalopram was still brand-only, the price difference was substantial and often pushed prescribers toward generic citalopram. Today, the price gap between generic versions is small to negligible at most pharmacies, though it can vary depending on your insurance formulary.
An economic analysis comparing the two found that escitalopram actually cost less than citalopram when total healthcare costs were considered, primarily because escitalopram-treated patients had lower hospitalization rates. In that analysis, citalopram was “dominated” by escitalopram, meaning it was both more expensive overall and less effective.19PubMed. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder A separate Italian cost-effectiveness evaluation found that escitalopram produced a small quality-of-life advantage over citalopram at slightly lower total cost over 12 months.20PubMed Central. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy These analyses assumed comparable drug prices, which is now essentially the reality in the generic market.
Agitation in Alzheimer’s Disease
One area where the assumption that escitalopram can seamlessly replace citalopram has been challenged is in treating agitation associated with Alzheimer’s disease. Citalopram had shown some promise for this use in earlier research, leading clinicians to assume escitalopram would work similarly with a cleaner cardiac safety profile. A phase 3 randomized trial put this to the test and found that escitalopram was not effective for treating agitation in Alzheimer’s, and it was associated with QT prolongation in this population.21Nature Medicine. Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
A systematic review and meta-analysis looking at both drugs for Alzheimer’s agitation found no significant improvement in agitation severity or cognitive outcomes with either SSRI. Both drugs were associated with similar rates of serious adverse events and treatment discontinuation, but SSRI use was linked to a significantly increased risk of falls, with a nearly 80% higher rate.22PubMed. Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials This is a useful reminder that “newer and purer” doesn’t automatically mean “better for every use.” The two drugs may share most of their pharmacology, but their effects can diverge in unexpected ways in specific populations.
Why Citalopram Prescriptions Keep Declining
Despite the two drugs sharing the same core molecule, citalopram prescribing has been falling steadily while escitalopram use climbs. The 2011 FDA safety communication about citalopram’s QT risk was a turning point, prompting many prescribers to switch existing patients to escitalopram and start new patients on it by default. Analysis of prescribing trends confirms that declining rates of citalopram prescription have continued even though both drugs have similar adverse-effect profiles in everyday use and comparable generic pricing.23PubMed Central. Rise of escitalopram and the fall of citalopram
Interestingly, one study of Medicare patients found that adherence, measured by how consistently patients filled their prescriptions, was actually lower in the escitalopram group at both six months and one year compared to alternatives.24PubMed Central. Assessing the Comparative-Effectiveness of Antidepressants Commonly Prescribed for Depression in the US Medicare Population This is a surprising finding that cuts against the “escitalopram is simply better” narrative. Real-world adherence depends on factors that randomized trials can’t fully capture: how the medication feels subjectively, out-of-pocket costs at the pharmacy, prescriber follow-up, and individual tolerance. A drug that performs well in controlled trials can still lose patients in the messy reality of daily life.
For anyone currently taking citalopram and wondering whether to ask about switching, the honest assessment is this: escitalopram has a modest but real statistical edge in efficacy and speed, a cleaner cardiac safety profile, and broader FDA-approved indications. But if citalopram is working for you without problems, the expected benefit of switching is small. The people most likely to gain from a switch are those on higher citalopram doses who bump up against the 40 mg ceiling, older adults with cardiac risk factors, and patients with GAD who want a drug with dedicated trial evidence for their condition.